Get In Touch with Augment Biologics
Please tell us a little bit about yourself and why you'd like to get connected. Augment Biologics + SOSV will follow up with you via email.
Life is programmed by three classes of biopolymers: polynucleotides (DNA/RNA), polypeptides (proteins), and polysaccharides (glycans). We’ve learned to “write” genes and proteins like software, but glycosylation is still a finicky, expensive manufacturing problem. That’s a big deal: the wrong glycan can slash an antibody’s efficacy, trigger allergic reactions, or turn a multi-million-dollar batch into scrap. And it’s everywhere, 50%+ of newly approved drugs are glycosylated.
Augment Biologics has built a first-of-its-kind AI foundation model for glycoprogramming: predicting a handful of non-obvious amino-acid edits (e.g., ~4 changes in a 1,500-aa protein) that reliably encode precise, valuable glycosylation in the product itself — reducing reliance on fragile bioreactor control. This unlocks a >$200B U.S. monoclonal antibody market, protecting franchises like Merck’s Keytruda and refreshing aging blockbusters.
It works — In a first set of 10 tested sequences for a never-seen-before glycosylation modification, 5+ constructs blew past the biomanufacturing state of the art and left behind in the dust a current blockbuster drug produced from human blood donations We went from 0% to 80% of critical glycosylation!
Already, Augment is in talks with 5 top pharmaceutical companies and has signed a partnership agreement with a leading CDMO. We are incredibly excited about this company – not only for the fundamental problems it can solve for the biomanufacturing and biotherapeutics markets – but also for the broad business opportunity that Augment faces. This is a platform company with enormous leverage.

Making glycosylation control a software solution to unlock a >$200B monoclonal antibody market.
We were able to program an antibody glycan that people have been trying to engineer for 20 years. In 2 months...
Please tell us a little bit about yourself and why you'd like to get connected. Augment Biologics + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.